Toby Paulson, DO
Cardiovascular Disease · American Fork, UTNPI 1235264169
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,500 of the $19,492 with a category attached, or 69.3%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 70.2% of it on its own, with 32 other manufacturers making up the rest. 2025 is the largest year on record at $11,419, more than ten times the $828 reported in 2019. Among cardiovascular disease clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 337 payments — averaging $57.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$14K
- Pfizer$814
- Abbott$652
- Novartis$598
- Amgen$551
- Boston Scientific$403
- plus $3K from 27 others
What the payments were for
- Speaking & faculty fees$13,50069%
- Food & beverage$5,97031%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 30 | $13,687 |
| Pfizer | 55 | $814 |
| Abbott | 22 | $652 |
| Novartis | 36 | $598 |
| Amgen | 27 | $551 |
| Boston Scientific | 23 | $403 |
| Boehringer Ingelheim | 22 | $377 |
| Actelion Pharmaceuticals US, Inc. | 13 | $326 |
| Bayer | 12 | $298 |
| Johnson & Johnson | 17 | $263 |
| E.r. Squibb & Sons, L.L.C. | 13 | $247 |
| Baxter Healthcare | 5 | $178 |
| AstraZeneca | 11 | $149 |
| Merck | 6 | $121 |
| Amarin Pharma, Inc. | 5 | $103 |
| Sanofi-aventis U.S. LLC | 5 | $85 |
| Esperion Therapeutics, Inc. | 6 | $80 |
| Edwards Lifesciences | 3 | $76 |
| Alnylam Pharmaceuticals Inc. | 2 | $53 |
| Regeneron Healthcare Solutions, Inc. | 3 | $51 |
| Lexicon Pharmaceuticals, Inc. | 2 | $48 |
| Gilead | 3 | $47 |
| United Therapeutics Corporation | 3 | $46 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Scpharmaceuticals Inc. | 1 | $34 |
| Teleflex LLC | 2 | $33 |
| Cvrx, Inc. | 1 | $30 |
| Inari Medical, Inc. | 1 | $25 |
| Philips North America LLC | 2 | $23 |
| Biotronik Inc. | 1 | $18 |
| Sanofi | 1 | $16 |
| CMP Pharma, Inc. | 1 | $15 |
| Inspire Medical Systems, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$13,500
- Confirm Rx$113
How this compares
$19,492 in reported general payments places this provider in the 90th percentile of 131 cardiovascular disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 103 | $87,153 |
| XareltoRivaroxaban | 63 | $69,642 |
| JardianceEmpagliflozin | 78 | $63,256 |
| EliquisApixaban | 71 | $61,113 |
| CorlanorIvabradine Hcl | 24 | $17,130 |
| FarxigaDapagliflozin Propanediol | 12 | $15,911 |
| Repatha SureclickEvolocumab | 22 | $14,185 |
| MultaqDronedarone Hcl | 15 | $13,223 |
| Nebivolol Hcl | 57 | $2,607 |
| Midodrine Hcl | 50 | $2,027 |
| Sodium Chloride0.9 % Sodium Chloride | 146 | $1,972 |
| Carvedilol | 167 | $1,786 |
| Prasugrel Hcl | 35 | $1,743 |
| Promethazine Hcl | 42 | $1,702 |
| Flecainide Acetate | 55 | $1,413 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $598 | $87,153103 claims |
| Johnson & JohnsonXarelto | $263 | $69,64263 claims |
| Boehringer IngelheimJardiance | $377 | $63,25678 claims |
| PfizerEliquis | $814 | $61,11371 claims |
| AmgenCorlanor | $551 | $17,13024 claims |
| AstraZenecaFarxiga | $149 | $15,91112 claims |
| Sanofi-aventis U.S. LLCMultaq | $85 | $13,22315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 131 cardiovascular disease providers in Utah.
Other cardiovascular disease in American Fork
- Melvin CarterAmerican Fork$4K
- John RyanSalt Lake City$1.4M
- Robert FowlesSalt Lake City$611K
- Brian WhisenantMurray$416K
- Andrew BehuninDraper$192K
- Jeffrey OsbornSalt Lake City$69K
- James FangSalt Lake City$67K
- Joseph MuhlesteinMurray$65K
- Hannah RaaschSalt Lake City$62K
- Divya Ratan VermaMurray$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.